Mirvetuximab soravtansine-gynx beneficial for FRα-positive ovarian cancer, finds phase 3 trial

by

For patients with high folate receptor α (FRα)-positive ovarian cancer, a first-in-class antibody-drug conjugate targeting FRα, mirvetuximab soravtansine-gynx (MIRV), shows a significant benefit over chemotherapy, according to a study published in the Dec. 7 issue of the New England Journal of Medicine.

Leave A Comment

Your email address will not be published. Required fields are marked *